comparemela.com

Latest Breaking News On - Prnewswire nouscom - Page 1 : comparemela.com

Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer

BASEL, Switzerland, Jan. 5, 2023 /PRNewswire/ Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced that it has entered

United statesEleanor perkinPrnewswire nouscomMarwang fakihRichard davisSylvie berrebiBristol myers squibbMarina udierMerck co incMerck sharp dohmeJanssen research developmentMicrosatellite instable highMetastatic colorectal cancerChief executive officerMerck sharpProfessor marwan

Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an off-the shelf Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer

BASEL, Switzerland, Nov. 15, 2022 /PRNewswire/ Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced the first patient

United statesEleanor perkinPrnewswire nouscomRick davisMarwang fakihSylvie berrebiBristol myers squibbMichaelj overmanMarina udierKostenloser wertpapierhandelUniversity of texas md anderson cancer centerDepartment of gastrointestinal medical oncologyJanssen research developmentMicrosatellite instable highPrincipal investigatorGastrointestinal medical oncology

Nouscom s Personalized Neoantigen Cancer Immunotherapy NOUS-PEV Demonstrates Promising Safety, Immunogenicity and Anti-tumor Activity in Solid Tumors

/PRNewswire/ Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced interim data from.

Eleanor perkinPrnewswire nouscomRick davisOliver bechterSylvie berrebiBristol myers squibbSven gogovSociety for immunotherapy of cancerLeuven cancer institute belgiumJanssen research developmentAnnual meetingPrincipal investigatorGeneral medical oncologyLeuven cancer instituteChief medical officerPresentation details

Nouscom announces leading publication revealing an immune mechanism of action driving anti-tumor activity of adenovirus vectored vaccines and anti-PD1 immunotherapy

/PRNewswire/ Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announces the.

United statesEleanor perkinRick davisPrnewswire nouscomSylvie berrebiElisa scarselliAmerican association for cancer researchAmerican society clinical oncologyCandiolo cancer instituteHead of the armenise harvard laboratory immunoregulationItalian institute for genomic researchArmenise harvard laboratory of immunoregulationScience translational medicineArmenise harvard laboratoryLuigia paceAmerican association

Nouscom Announces Positive Full Phase 1 Data of NOUS-209, an off-the-shelf Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

/PRNewswire/ Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced.

United statesEleanor perkinPrnewswire nouscomRick davisMarwang fakihSylvie berrebiMarina udierAmerican association for cancer researchAmerican society of clinical oncologyClinical oncologyAnnual meetingMicrosatellite instable highAmerican associationCancer researchMedical oncology specialistDuarte california

vimarsana © 2020. All Rights Reserved.